Abstract Purpose: To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) and to characterize the relationship between LEP-ETU concentrations and the time course of neutropenia in cancer patients. Experimental Design: LEP-ETU was administered to 88 patients and 63 were evaluable for pharmacokinetic/pharmacodynamic (PK/PD) analysis following 1.5-and 3-h infusions every 3 weeks (q3w; dose range, 135-375 mg/m 2 ). MTD was identified using a 3 + 3, up-and-down dose-finding algorithm. PK/PD modeling was done to describe the temporal relationship between paclitaxel concentrations and neutrophil count. Simulations assessed the influence of dose and schedule on neutropenia severity to help guide dose selection. Results: The MTD of LEP-ETU was identified as 325 mg/m 2 . DLTs occurring at 375 mg/m 2 consisted of febrile neutropenia and neuropathy. The C max and area under the plasma concentration-time curve of LEP-ETU were less than proportional with increasing dose. The PK/PD model showed that LEP-ETU inhibition of neutrophil proliferation was 9.1% per 10 Ag/mL of total paclitaxel concentration. The incidence of grade 4 neutropenia increased from 33% to 42% across the dose range of 275 to 325 mg/m 2 q3w. For a dose of 110 mg/m 2 given weekly, grade 4 neutropenia was estimated to be 16% compared with 42% for the same total dose administered q3w. Conclusions: LEP-ETU can be administered safely at higher doses than Taxol. Modeling and simulation studies predict that 325 mg/m 2 LEP-ETU q3w provides acceptable neutropenic events relative to those observed at 175 mg/m 2 Taxol q3w. A 275 mg/m 2 dose may offer an improved therapeutic index.
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Paclitaxel is an anticancer agent that prevents cell division by promoting the assembly and stabilization of microtubules (1, 2) . The drug is used widely in the treatment of breast, ovarian, and non-small cell lung cancer. Due to its poor aqueous solubility, paclitaxel is dissolved in dehydrated ethanol and polyethoxylated castor oil (Cremophor EL), which has been shown to cause hypersensitivity reactions (3) . Premedication with glucocorticoids and antihistamines is necessary to minimize such reactions. Additional toxicities associated with paclitaxel include peripheral neuropathy, neutropenia, alopecia, mucositis, arthralgias, and myalgias. These side effects limit dose intensification and often require reduction of dosing, which can potentially affect drug efficacy.
Liposomes are an alternate drug delivery system that has been used to enhance the therapeutic efficacy and reduce the toxicity of several anticancer agents, including doxorubicin (4) . Liposome-entrapped paclitaxel easy-to-use (LEP-ETU) is a liposomal formulation of paclitaxel designed to increase safety and tolerability while potentially delivering higher doses of paclitaxel. In mouse models, LEP has shown equal or superior efficacy in inhibiting tumor growth compared with paclitaxel in several tumor types (5 -8) .
Historically, pharmacokinetic/pharmacodynamic (PK/PD) models have been used to describe relationships between exposure measures and chemotherapy-induced myelosuppression, including correlations between the nadir neutrophil count and area under the plasma concentration-time curve or time elapsed above a threshold concentration (9, 10) . More recently, PK/PD models have been developed to characterize the temporal relationship between drug concentration and changes in neutrophil count (11 -15) . The current clinical practice of administering paclitaxel in part includes empirical dose adjustments based on nadir neutrophil counts. A better understanding of the temporal relationship between circulating neutrophils and paclitaxel concentrations might provide a basis for optimizing the development of new drug formulations such as LEP-ETU.
The goals of the phase I development of LEP-ETU administered as a 1.5-h infusion every 3 weeks (q3w) were to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) and to characterize the pharmacokinetics of LEP-ETU. An additional objective was to develop a mechanismbased model describing the temporal relationship between circulating neutrophils and paclitaxel concentrations. Using this PK/PD model, simulations were done to assess the effect of dose, infusion duration, and schedule of LEP-ETU on the severity of neutropenia.
Patients and Methods
Eligibility criteria. Patients were eligible if they had histologically confirmed, locally advanced or metastatic carcinoma, an Eastern Cooperative Oncology Group performance status of V2, and were z18 years old. Requirements for adequate organ function included an absolute neutrophil count (ANC) of z1,500/AL, platelets z100,000/AL, hemoglobin z9.0 g/dL, creatinine V2.0 mg/dL, total bilirubin V1.5 times the upper limit of normal, and alanine aminotransferase and aspartate aminotransferase V2.5 times the upper limit of normal. Other eligibility criteria included no prior chemotherapy or radiotherapy within 3 weeks of treatment. Patients were excluded if they had grade z2 neuropathy, symptomatic brain metastases, or hypersensitivity to paclitaxel or liposomes. Patients with prior exposure to taxanes were eligible. The protocol was approved by the institutional review board at each participating institution. All patients gave written informed consent before treatment.
Study design. This was a phase I, multi-institutional, open-label study of LEP-ETU administered as a 1.5-h infusion q3w. The starting dose of LEP-ETU was 135 mg/m 2 . At least 3 patients were enrolled at each dose level. If none of the 3 patients experienced a DLT, the dose was escalated. If 1 of the 3 patients developed a DLT, 3 additional patients were enrolled at the same dose level. If one-third or more patients developed a DLT at a given dose level, a total of 6 patients were treated at the previous dose level. The MTD was defined as the dose level below that at which one-third or more patients experienced a DLT. Treatment continued until disease progression, withdrawal of consent, or unacceptable toxicity.
Also, in the phase I study, an additional cohort was treated with 175 mg/m 2 LEP-ETU as a 3-h infusion q3w to compare the pharmacokinetic and myelosuppression characteristics of paclitaxel from LEP-ETU and Taxol. Additional patients were obtained from a crossover bioequivalence study where patients were randomized to receive either one cycle of LEP-ETU followed 3 weeks later by one cycle of Taxol or one cycle of Taxol followed 3 weeks later by one cycle of LEP-ETU (16) .
Treatment. LEP-ETU was supplied by NeoPharm as a lyophilized cake containing 30 mg paclitaxel. It was prepared for administration by reconstitution in 12.5 mL sterile water for injection to yield 2 mg/mL paclitaxel and diluted in 0.9% normal saline. It was recommended the infusion bag be inverted several times to achieve a uniform cloudy white dispersion during reconstitution and infusion. LEP-ETU was administered without in-line filtration. As a precaution to prevent infusion-related reactions (IRR), patients enrolled at 135 to 225 mg/m 2 were given premedication (dexamethasone and histamine blockers). Due to the low occurrence of breakthrough IRRs in the initial cohorts, patients who received z275 mg/m 2 did not receive concomitant treatment with antihistamines or glucocorticoids on the day of infusion unless they experienced an IRR.
Patient assessments. Toxicities were evaluated and graded using National Cancer Institute Common Terminology Criteria version 3.0. A DLT was defined during cycle 1 as grade 4 neutropenia z3 days, grade z3 neutropenia of any duration with infection or fever z38.5jC, grade 3 thrombocytopenia, grade z2 neurosensory or neuromotor toxicity, and all other grade z3 nonhematologic toxicity or grade z4 hematologic toxicity.
At baseline, a history, physical examination, chest X-ray, electrocardiogram, and laboratory tests (including a complete blood count with differential, chemistry, and urinalysis) were obtained. Complete blood counts were drawn twice weekly and chemistry weekly in cycle 1. In subsequent cycles, complete blood counts were obtained weekly and chemistry before each cycle. Imaging of involved cancer sites was done within 4 weeks of enrollment and after every two cycles. Response was assessed using RECIST (17) .
Pharmacokinetic sampling, assay, and analysis. In the dose escalation cohorts, serum samples for pharmacokinetics were collected on day 1 pre-dose and 45 min after the start of infusion, immediately before end of infusion, and at 5, 15, and 30 min, and 1, 2, 3, 4, 6, 8, 12 or 20, 48, 96, 168, and 336 h after the end of the infusion. In the bioequivalence study, serum samples were obtained during cycle 1 predose, 60, 120, and 165 min during the infusion, 15, 30, 45 min after the infusion, and 1, 2, 4, 6, 8, 22, 44, and 68 h after the end of the infusion.
Docetaxel was added to samples as the internal standard. Analytes were extracted from plasma using liquid-liquid extraction, eluted with acetonitrile, evaporated under nitrogen gas, and reconstituted. Highperformance liquid chromatography with mass spectrometry was used to quantify the plasma concentration of paclitaxel (as a measure of total drug; ref. 18) . During and after the study, an attempt to develop a validated assay for measuring free paclitaxel from a liposomal formulation was deemed to be analytically challenging and not feasible. The lower limit of quantification was 5 ng/mL and the validated calibration range was 5 to 1,000 ng/mL for total paclitaxel.
Data analysis. Data from the dose escalation (n = 30 patients) and bioequivalence (n = 33 patients) trials were combined for the PK/PD analysis of neutropenia (total of 63 patients). Population PK/PD modeling of the pharmacokinetics of total paclitaxel and the time course of ANC following LEP-ETU administration was done using a two-stage sequential approach (19) . The pharmacokinetics of total paclitaxel was individually fit for each patient as the dosing cohorts completed in each of the two trials using WinNonlin Pro version 3.1. This approach enabled the completion of reporting real-time pharmacokinetic variables for individual patients during the course of the clinical trials before obtaining the neutropenia data at the completion of each trial. Subsequently, it was decided to pursue only the pharmacodynamic modeling component using NONMEM with the first-order with the post-hoc option and first-order conditional estimation with interaction approximation methods (20) ; thus, this method was sufficient to make decisions during clinical development of LEP-ETU. Exploratory analyses and graphical displays, including evaluation of NONMEM outputs, were done using SAS version 8.2 and S-PLUS server version 7.03. For hierarchical models, a decrease in the minimum value of the objective function of z7.88 represented a statistically significant difference (a = 0.005) for the addition of one variable (df = 1). The goodness-of-fit of the PK/PD models was assessed by examination of several diagnostic plots. The final model was evaluated using a simulation-based visual predictive check method (21, 22) . Correlation between interindividual variability terms was assessed and the appropriateness of residual variability models was also evaluated.
PK/PD neutropenia model. A three-compartment pharmacokinetic model was used to describe the pharmacokinetics of paclitaxel in blood following LEP-ETU administration ( Fig. 1;ref. 23 ). The pharmacokinetic model consisted of linear elimination from the central compartment and linear distribution from the central to two peripheral compartments, representative of highly and less perfused tissues. During the pharmacokinetic modeling stage of this analysis, distribution and elimination rate constants (a, b, c, k 21 , and k 31 ) and central volume of distribution (V c ) were estimated for each individual. For the pharmacodynamic modeling of neutropenia, all of the individual values of the pharmacokinetic variables were fixed for each patient and the predicted individual paclitaxel concentrations-time profiles were used as input functions into this PK/PD model. The variables, mean neutrophil transit time (MTT), Slope, ANC 0 , and u, were simultaneously estimated in the pharmacodynamic modeling part. This sequential modeling approach was selected over a simultaneous PK/ PD estimation to expedite the pharmacodynamic modeling by using the existing individual estimates of pharmacokinetic variables.
Based on a PK/PD model developed previously to characterize the time course of ANC following chemotherapy, a precursor-dependent indirect pharmacodynamic response model, including three transit compartments, was fit to the data following paclitaxel administration ( Fig. 1; ref. 12 ). Following several steps of hematopoiesis, including proliferation, differentiation, and maturation, the model describes the release of progenitor cells from the bone marrow [Prol] into transit compartments [Transit] that allow for the time delay in the transfer of mature neutrophils that circulate in the blood [Circ] . Constant neutrophil production is characterized by a first-order rate constant, k Prol , which can be affected by a stimulatory feedback mechanism that modulates the rebound effect based on the circulating neutrophil count. The feedback mechanism is modeled as [ANC 0 / ANC] B , the change in the ratio of baseline circulating neutrophils when no drug is present to observed circulating cells at any given time. This feedback results in an increase in the proliferation rate of progenitor cells in bone marrow at low concentrations of circulating neutrophils. The exponent of the feedback function (u) determines the magnitude of the influence of the feedback. Maturing neutrophils produced in bone marrow [Prol] are transferred to transit compartments [Transit] to account for the time delay between proliferation and maturation according to firstorder processes characterized by k tr and are removed from the blood following a first-order process characterized by k circ . Based on the paclitaxel's mechanism of action of cell cycle blockade at the G 2 -M interphase, the drug's cytotoxic effect on the bone marrow is represented by formation of a drug-cell complex resulting in inhibition of the proliferation rate of progenitor cells in bone marrow by a linear function of paclitaxel blood concentrations, denoted by an inhibitory linear slope model (1 -SLOPE * C p ). C p is the predicted paclitaxel blood concentration. The MTT (estimated as MTT = nþ1 ktr , where n is the number of transit compartments) represents the time for a neutrophil to reach the circulation after leaving the bone marrow.
The interindividual variability in the PK/PD model variables was assumed to follow a log-normal distribution; consequently, exponential error models were used. The magnitude of the residual variability in the ANC values was modeled using a log error model and the magnitudes of both interindividual variability and residual variability were expressed as percent coefficients of variation. Simulations to assess the effect of dose, schedule, and infusion duration on ANC. To evaluate the effect of paclitaxel on the incidence and duration of neutropenia following administration of LEP-ETU, different scenarios were selected to explore the role of the dose, schedule, and infusion duration on the time course of neutrophils in cancer patients. Using the final PK/PD model, final estimates of the model variables, and their variabilities, simulations were done. ANC profiles for a total of 500 patients at each dose level and schedule were simulated following administration of 0.5-and 1.5-h infusions of 275, 290, 300, 310, and 325 mg/m 2 liposomal paclitaxel q3w and 0.5-and 1.5-h infusions of 90, 100, and 110 mg/m 2 weekly for 3 of 4 weeks for two cycles in the absence of any dose reductions. For every patient, body weight, body surface area, and gender were assigned by resampling individual covariate vectors from the patient covariate dataset. The 5th and 50th percentiles of the simulated ANC profiles were plotted to compare the time course of ANC and its variability after the administration of the dosing regimens evaluated. The incidence of grade 3 and 4 neutropenia was calculated and subsequently compared across doses and regimens.
Results
Patient characteristics. Thirty patients were enrolled in the phase I trial at three centers and 58 patients in a bioequivalence study at six centers ( Table 1 ). The most common tumor types included cancers of the breast (16%) and ovary (10%). Nearly all of the patients (99%) had received prior chemotherapy with 53% receiving z3 prior chemotherapy regimens. No patients remain on study. The median number of cycles administered was 4 (range, 1-21). , one of the first three patients experienced a DLT of febrile neutropenia. Three more patients were accrued at this level with no additional observations of DLTs; thus, the dose was escalated to 375 mg/m 2 . Two of six patients treated at this level experienced a DLT, one developed grade 3 motor neuropathy and one patient had grade 4 neutropenia, each having received one cycle of therapy (Table 2A) . Thus, the MTD for LEP-ETU administered as a 1.5-h infusion q3w was defined as 325 mg/m 2 .
Toxicities. In the phase I trial, the majority of nonhematologic effects were grades 1 and 2 across the entire dose range (Table 2B) . No patient experienced grade 4 nonhematologic toxicity. Fatigue, nausea, vomiting, diarrhea, myalgias, and arthralgias were common but mild. Peripheral neuropathy was more common at the higher dose levels, appearing in one-third of the patients treated at 325 mg/m 2 (one grade 1 and one grade 2) and in two-thirds of the patients treated at 375 mg/m 2 (two grade 2 and one grade 3). Six patients reported grade V2 sensory symptoms, such as burning sensation, hypoaesthesia, paresthesia, hyporeflexia, and/or areflexia related to study drug. With regard to hematologic toxicities, the frequency and severity of myelosuppression were generally dose dependent. One patient developed febrile neutropenia at 325 mg/m 2 on day 6 of cycle 1 and two patients experienced grade 4 neutropenia (one at 325 mg/m 2 and the other at 375 mg/m 2 ) during cycle 1. Of the 157 treatment cycles administered, 3% resulted in an ANC nadir <500/AL. In one case treated at a dose of 325 mg/m 2 , the platelet count dropped below 25,000/AL with a platelet nadir of 23,000/AL during cycle 1. No patients received growth factor support. Seven (23%) patients experienced grade 1/2 IRR, which required interruption of LEP-ETU infusion and one additional patient experienced rigors f6 hours after the end of infusion. No patients discontinued from the study because of IRR. In the bioequivalence study, grade 4 neutropenia was observed in five patients and one patient experienced febrile neutropenia. There was no occurrence of thrombocytopenia. No episodes of grade z2 neuropathy or IRRs were reported.
Pharmacokinetics. Thirty patients from the phase I study and 33 patients from the bioequivalence trial were evaluable for pharmacokinetics. Following liposomal paclitaxel administration, paclitaxel blood concentrations displayed triexponential decay, representative of rapid tissue distribution followed by slower elimination, with a mean terminal half-life in blood of 26 h (Fig. 2A) . The primary modeled pharmacokinetic variables of a, b, c, k 21 , and k 31 and V c were fitted with reasonable precision and accuracy (Supplementary Table S1 ). Median area under the plasma concentration-time curve was less than proportional with increasing dose. Volume of distribution at steady-state and clearance decreased with increasing dose. Analyses of data from the bioequivalence study indicated that the relative bioavailability of LEP-ETU compared with Taxol was 85% (90% confidence interval, 91-103%) and 97% (90% confidence interval, 80-90%) for area under the plasma concentration-time curve and C max , respectively (results not shown).
PK/PD model for neutropenia. The drug's pharmacologic action of cell cycle blockade was incorporated into the model through inhibition of the proliferation rate of progenitor cells in the bone marrow as a linear relationship with paclitaxel blood concentration. Individual model-predicted and observed ANC concentrations versus time illustrate that the model adequately characterizes the observed data following several cycles of therapy (Fig. 2B) . Using the first-order estimation method, population mean variables of MTT, Slope, ANC 0 , and u were estimated with good precision (RSE% < 11%), and interindividual variability was 53%, 66%, and 41% for MTT, Slope, and ANC 0 , respectively, suggesting that not all patients experienced the same neutropenic effect following liposomal paclitaxel administration (Supplementary Table S2 ). Before chemotherapy, the population mean ANC value was 4.34 Â 10 9 /L, representative of a normal neutrophil count. MTT was estimated to be f80 h, which is reasonable for a postmitotic time delay to maturation of neutrophils. Based on the MTT, k circ is 0.05 L/h, reflective of an elimination neutrophil plasma half-life of f14 h, similar to published values of f6.7 h (24). The drug effect (Slope) on the proliferation rate constant, k Prol , was decreased by 9.1% per 10 Ag/mL of total paclitaxel plasma concentration, indicative of the pronounced effect that paclitaxel has on the inhibition of progenitor cell production in bone marrow. The population mean value of the exponent of the degree of feedback, u, was 0.132.
A visual predictive check was also done for the 275 and 325 mg/m 2 dosing groups to assess the adequacy of the PK/ PD model (Fig. 2C) . The simulated prediction intervals illustrate that f54% of the observed data is encompassed within the 5th to 50th percentiles of the simulated data, supporting the adequacy of the overall model fitting the observed ANC values (Supplementary Table S3 ). The final PK/ PD model was rerun using the first-order conditional estimation with interaction estimation method. One of the key findings included multiple high correlations between many pharmacodynamic variables that were not observed in the first-order method (results not shown). In addition, the condition number based on the eigenvalues was high (approximate = 7,043) compared with the value observed using the first-order method (approximate = 91), suggesting the first-order conditional estimation method with our model was ill conditioned. Also, diagnostic plots of individual predicted versus observed ANC, population predicted versus observed ANC, weighted residuals versus individual predicted ANC, and weighted residuals versus population predicted ANC were similar between the two models using either the first-order or first-order conditional estimation methods. Based on these results, we conclude that the first-order estimation method for our data collected is more appropriate.
Model-based simulations. Simulations incorporating interindividual variability and residual variability show the time course of neutropenia following two cycles of liposomal paclitaxel treatment (Fig. 3A-C) . Comparing the q3w to once weekly schedules, a larger percent of patients are expected to experience more severe neutropenia with the q3w regimen. Independent of infusion duration, the incidence of grade 3 toxicity marginally increased within the dose range of 275 to 325 mg/m 2 (61-65%; Table 3 ). Interestingly, for a total cumulative dose of 300 mg/m 2 over 3 weeks, the incidence of grade 3 and 4 neutropenia was 48% and 14% compared with 64% and 38% on the q3w regimen, respectively. Altering the infusion duration from 1.5-to 0.5-h had no effect on either the incidence or the severity of neutropenia.
Antitumor activity. In the phase I study, partial responses were observed in four patients (ovary, 225 mg/m 2 dose level; endometrial, 325 mg/m 2 ; adenocarcinoma of unknown primary, 325 mg/m 2 ; and breast, 375 mg/m 2 ). None had received treatment with paclitaxel previously. There were 12 patients with a variety of tumor types who had stable disease after receiving z4 cycles. In the bioequivalence study, four partial responses occurred and 17 patients experienced stable disease.
Discussion
This is the first publication of the pharmacokinetic studies of a Cremophor-free, liposomal paclitaxel formulation. The MTD of LEP-ETU was 325 mg/m 2 on a q3w schedule. This dose is higher than that achieved with Taxol, which is typically delivered at a dose range of 135 to 200 mg/m 2 every 3 weeks. The DLTs observed for LEP-ETU were typical taxane-associated side effects, including peripheral neuropathy and myelosuppression.
A theoretical advantage of a liposomal agent is an improved therapeutic index. A major obstacle to administration of paclitaxel is neuropathy. In the phase I study, neurotoxicity occurred in 5 of 12 patients treated with LEP-ETU at z325 mg/m 2 . Although a direct comparison with Taxol administered at these doses is not possible, the neuropathy caused by LEP-ETU appears to be no worse than that reported for Taxol on a q3w schedule (25) . A larger study would be necessary to further evaluate the efficacy and better characterize the prevalence of peripheral neuropathy of LEP-ETU. In addition, LEP-ETU can be given without steroid or antihistamine premedication. Among the patients treated with LEP-ETU on the phase I study, 23% experienced IRRs and this incidence appears to be no worse than that observed with Taxol at similar doses.
Following LEP-ETU administration, paclitaxel blood concentrations declined polyexponentially and paclitaxel area under the plasma concentration-time curve was less than proportional with increasing dose, which is similar to polyoxyethylated castor oil -based paclitaxel (9, 10) . In these studies, total paclitaxel was quantitated and thus, in part, could explain the similar pharmacokinetic profiles and overall total exposure between paclitaxel and LEP-ETU, which has also been observed in preclinical liposomal formulations of paclitaxel (26) . Although similarities exist between the plasma pharmacokinetics of the two formulations when comparing total paclitaxel (free plus bound), differences in pharmacokinetics potentially exist in the degree of tissue distribution of liposomal paclitaxel (26) . The nonlinearity of LEP-ETU pharmacokinetics could be related to the retainment of paclitaxel within the liposome and sequestration by the reticuloendothelial system. As a result, the proposed changes in tissue distribution of paclitaxel due to liposome encapsulation may provide an explanation for the observed increase in the MTD for LEP-ETU of 325 mg/m 2 . The PK/PD model was developed to characterize the time course of neutropenia in relation to paclitaxel exposure (12) . The pharmacokinetic data were modeled in real-time; thus, the variables for each patient were provided as each dosing cohort completed in the studies before availability of ANC data at study completion. Subsequently, the pharmacodynamic variables were simultaneously fit, whereas each individual's pharmacokinetic variables were fixed to the individual estimates. A visual predictive check confirmed that the model adequately characterize the ANC time course data. As a result of using the sequential two-stage approach to fitting the PK/PD model, which allowed for improved model stability during estimation, the overall standard errors of each PK/PD variable may be less than the true error associated with each variable. This approach allows for improved model stability during estimation.
The pharmacodynamic variable estimates of MTT, Baseline, u, and Slope for paclitaxel following administration of liposomal paclitaxel were comparable but lower than the model variables for the Cremophor-based formulation of paclitaxel, respectively (79.7 versus 127 h for MTT, 4.3 versus 5.2 Â 10 9 /L for baseline ANC, and 0.13 versus 0.23 for c; ref. 12). Furthermore, unexplained residual variability was 46% and 40% for the LEP-ETU and Taxol pharmacodynamic models, respectively. Only the slope variable, measuring the drug's effect on inhibiting progenitor cell division, was f2-fold higher for the Cremophor-based formulation, which may be in part suggest the inherent differences of the two formulations in altering the effect of paclitaxel on neutropenia.
Based on the PK/PD model results, there was a linear relationship between total paclitaxel concentrations and drug effect. The estimate of the drug-related variable, Slope, was slightly less than 1, indicating that the inhibitory effect on neutrophils within the concentration range achieved with the q3w dosing regimen is approximately concentration proportional. The maximum drug effect quantified by the SLOPE * C p function was higher than 1, indicating that paclitaxel reduced the proliferation rate and stimulated the killing rate of progenitor cells in bone marrow.
Model-based simulations revealed that neutropenia resulting from liposomal paclitaxel is likely to be dependent on the dose amount and schedule but not on the duration of infusion in the range studied. The simulations of 275 to 325 mg/m 2 q3w regimens also showed the pattern of diminishing neutrophil counts following drug administration with an expected nadir neutrophil count occurring at f8 days and 33% to 42% of the simulated patient population experiencing grade 4 neutropenia. In contrast, the incidence of grade 4 neutropenia is expected to be only 11% to 16% if liposomal paclitaxel is given weekly at 90 to 110 mg/m 2 . Also, the time below a given toxicity threshold (for instance, 1 Â 10 9 /L; grade 3) is predicted to be longer for the once weekly regimen.
The interdose interval is also important in determining the depth and recovery characteristics of the ANC time profile following drug administration. In comparing a 110 mg/m 2 1.5-h infusion weekly to 325 mg/m 2 1.5-h infusion administered q3w, the total dose administered in a 3-week period is similar at f571 and 562 mg, respectively, scaled to a body surface area of 1.73 m 2 . Simulations indicated a lower expected incidence of severe neutropenia (grade 4) with the weekly schedule (Fig. 3C ). Therefore, it is possible to reduce the degree of neutropenia associated with LEP-ETU by employing more frequent dosing while retaining the cumulative dose delivery.
Overall, these results support the idea that the severity and frequency of neutropenia is dose-and schedule-dependent following liposomal paclitaxel treatment, which makes ANC reduction predictable and manageable through complete blood count monitoring. Modeling and simulation studies predict that 325 mg/m 2 LEP-ETU q3w provides acceptable neutropenia outcomes comparable with those obtained following 175 mg/m 2 Taxol q3w. An increase in the amount of paclitaxel can be delivered with LEP-ETU at a phase II/III dose of 275 or 325 mg/m 2 without corticosteroid premedication on a q3w schedule. The 275 mg/m 2 dose may offer an improved therapeutic index. Based on these modeling and simulation results, a weekly schedule would be expected to result in less myelosuppression. As a result, the application of PK/PD modeling and simulation during phase I development exemplifies its role in guiding dose recommendations for future studies with LEP-ETU and potentially other anticancer drugs. Further studies evaluating the antitumor activity and tolerability of LEP-ETU are warranted. 
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